IL202660A0 - Lyophilized immunoglobulin formulations and methods of preparation - Google Patents
Lyophilized immunoglobulin formulations and methods of preparationInfo
- Publication number
- IL202660A0 IL202660A0 IL202660A IL20266009A IL202660A0 IL 202660 A0 IL202660 A0 IL 202660A0 IL 202660 A IL202660 A IL 202660A IL 20266009 A IL20266009 A IL 20266009A IL 202660 A0 IL202660 A0 IL 202660A0
- Authority
- IL
- Israel
- Prior art keywords
- preparation
- methods
- immunoglobulin formulations
- lyophilized
- lyophilized immunoglobulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92913307P | 2007-06-14 | 2007-06-14 | |
US12/138,075 US20090208492A1 (en) | 2007-06-14 | 2008-06-12 | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
PCT/US2008/066990 WO2008157409A1 (fr) | 2007-06-14 | 2008-06-13 | Formulations d'immunoglobuline lyophilisées et procédés de préparation |
Publications (1)
Publication Number | Publication Date |
---|---|
IL202660A0 true IL202660A0 (en) | 2011-08-01 |
Family
ID=40156638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL202660A IL202660A0 (en) | 2007-06-14 | 2009-12-10 | Lyophilized immunoglobulin formulations and methods of preparation |
Country Status (15)
Country | Link |
---|---|
US (1) | US20090208492A1 (fr) |
EP (1) | EP2167126A4 (fr) |
JP (1) | JP2010530003A (fr) |
KR (1) | KR20100038100A (fr) |
CN (1) | CN101827608A (fr) |
AU (1) | AU2008265930A1 (fr) |
BR (1) | BRPI0812561A2 (fr) |
CA (1) | CA2691855A1 (fr) |
CO (1) | CO6251275A2 (fr) |
EA (1) | EA201000018A1 (fr) |
EC (1) | ECSP099837A (fr) |
IL (1) | IL202660A0 (fr) |
MA (1) | MA31519B1 (fr) |
MX (1) | MX2009013558A (fr) |
WO (1) | WO2008157409A1 (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2397034A1 (fr) | 2005-07-14 | 2011-12-21 | Lithera, Inc. | Formulation lipolytique améliorée à libération prolongée pour le traitement régional des tissus adipeux |
PL2993186T3 (pl) | 2008-03-14 | 2020-02-28 | Biocon Limited | Przeciwciało monoklonalne i sposób jego otrzymywania |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
KR20120027031A (ko) * | 2009-06-18 | 2012-03-20 | 와이어쓰 엘엘씨 | 소형 모듈 면역제약용 동결건조 제제 |
PL3721904T3 (pl) * | 2009-11-20 | 2022-01-31 | Biocon Limited | Formulacje przeciwciała t1h |
US20110224176A1 (en) * | 2010-01-15 | 2011-09-15 | Lithera, Inc. | Lyophilized Cake Formulations |
BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
US9072668B2 (en) | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
WO2011147921A1 (fr) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Compositions stables multi-doses comprenant un anticorps et un agent conservateur |
PT2616090T (pt) * | 2010-09-17 | 2023-10-16 | Takeda Pharmaceuticals Co | Estabilização de imunoglobulinas através de formulação aquosa com histidina em ph fracamente ácido a neutro |
EA201270784A1 (ru) | 2010-11-24 | 2013-04-30 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | Монотерапевтические композиции селективного липофильного и бета-агониста длительного действия и способы косметического лечения ожирения и контурного выпячивания |
LT2691112T (lt) * | 2011-03-31 | 2018-07-25 | Merck Sharp & Dohme Corp. | Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai |
CA2868401C (fr) * | 2012-03-26 | 2021-08-24 | Sanofi | Preparations d'anticorps igg4 stables anti-cxcr5 |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
CN105189559B (zh) | 2013-03-15 | 2021-07-13 | 塔科达有限责任公司 | 抗体制剂及其用途 |
EP3024485B1 (fr) | 2013-07-23 | 2020-11-18 | Biocon Limited | Utilisation d'un partenaire de liaison de cd6 et procédé associé |
WO2017015198A1 (fr) * | 2015-07-17 | 2017-01-26 | Coherus Biosciences, Inc. | Formulations aqueuses stables de natalizumab |
JP7020913B2 (ja) | 2015-09-07 | 2022-02-16 | 持田製薬株式会社 | アルギン酸凍結乾燥製剤 |
WO2018068012A1 (fr) | 2016-10-07 | 2018-04-12 | Regeneron Pharmaceuticals, Inc. | Protéine lyophilisée stable à la température ambiante |
DK3529274T3 (da) | 2016-10-21 | 2024-06-17 | Biocon Ltd | Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus |
EP3618871A4 (fr) | 2017-05-02 | 2021-01-06 | Merck Sharp & Dohme Corp. | Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
WO2019198100A1 (fr) * | 2018-04-10 | 2019-10-17 | Dr. Reddy's Laboratories Limited | Formulation d'anticorps |
US12024561B2 (en) * | 2018-04-10 | 2024-07-02 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
US20210401982A1 (en) * | 2018-04-10 | 2021-12-30 | Dr. Reddy's Laboratories Limited | Stable formulations of therapeutic antibody |
JP2022532965A (ja) * | 2018-11-21 | 2022-07-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 高濃度タンパク質製剤 |
WO2020172002A1 (fr) | 2019-02-18 | 2020-08-27 | Eli Lilly And Company | Formulation d'anticorps thérapeutique |
CN112538111B (zh) * | 2020-12-09 | 2022-04-29 | 深圳市亚辉龙生物科技股份有限公司 | 新冠病毒单链抗体及质控品和制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6306404B1 (en) * | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
ES2338218T3 (es) * | 2001-07-25 | 2010-05-05 | Facet Biotech Corporation | Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab. |
PT3417875T (pt) * | 2003-02-10 | 2020-08-24 | Biogen Ma Inc | Formulação de imunoglobulinas e método de preparação das mesmas |
US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
-
2008
- 2008-06-12 US US12/138,075 patent/US20090208492A1/en not_active Abandoned
- 2008-06-13 KR KR1020107000761A patent/KR20100038100A/ko not_active Application Discontinuation
- 2008-06-13 WO PCT/US2008/066990 patent/WO2008157409A1/fr active Application Filing
- 2008-06-13 CA CA002691855A patent/CA2691855A1/fr not_active Abandoned
- 2008-06-13 BR BRPI0812561-9A2A patent/BRPI0812561A2/pt not_active IP Right Cessation
- 2008-06-13 EP EP08771083A patent/EP2167126A4/fr not_active Withdrawn
- 2008-06-13 EA EA201000018A patent/EA201000018A1/ru unknown
- 2008-06-13 CN CN200880102173A patent/CN101827608A/zh active Pending
- 2008-06-13 MX MX2009013558A patent/MX2009013558A/es not_active Application Discontinuation
- 2008-06-13 JP JP2010512402A patent/JP2010530003A/ja active Pending
- 2008-06-13 AU AU2008265930A patent/AU2008265930A1/en not_active Abandoned
-
2009
- 2009-12-10 IL IL202660A patent/IL202660A0/en unknown
- 2009-12-28 CO CO09147977A patent/CO6251275A2/es not_active Application Discontinuation
- 2009-12-30 EC EC2009009837A patent/ECSP099837A/es unknown
-
2010
- 2010-01-12 MA MA32510A patent/MA31519B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010530003A (ja) | 2010-09-02 |
EA201000018A1 (ru) | 2010-06-30 |
ECSP099837A (es) | 2010-01-29 |
EP2167126A1 (fr) | 2010-03-31 |
BRPI0812561A2 (pt) | 2014-10-29 |
AU2008265930A1 (en) | 2008-12-24 |
MA31519B1 (fr) | 2010-07-01 |
US20090208492A1 (en) | 2009-08-20 |
CN101827608A (zh) | 2010-09-08 |
KR20100038100A (ko) | 2010-04-12 |
EP2167126A4 (fr) | 2012-03-07 |
WO2008157409A1 (fr) | 2008-12-24 |
MX2009013558A (es) | 2010-03-08 |
CO6251275A2 (es) | 2011-02-21 |
WO2008157409A8 (fr) | 2010-03-11 |
CA2691855A1 (fr) | 2008-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL202660A0 (en) | Lyophilized immunoglobulin formulations and methods of preparation | |
IL262205A (en) | Protein formulations and methods for their preparation | |
IL195794A0 (en) | Lyophilized formulations of anti-egfr antibodies | |
IL255813A (en) | Compositions of 5-fluorocytosine and their uses | |
EP2152304A4 (fr) | Compositions thérapeutiques à base de nanoémulsion et leurs procédés d'utilisation | |
IL208457A0 (en) | Compositions and methods for the preparation of nanoemulsions | |
EP2212432A4 (fr) | Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation | |
EP2021455A4 (fr) | Système de préparation de cytoblocs et procédés d'utilisation associés | |
EP2099321A4 (fr) | Compositions de lait humain et procédés destinés à fabriquer et utiliser ces compositions | |
IL206978A0 (en) | Powdered protein compositions and methods of making same | |
HRP20160902T1 (hr) | Pripravci i postupci uporabe forbolskih estera | |
ZA201203709B (en) | Immunogenic compositions and methods | |
PL2066339T3 (pl) | Kompozycje i sposoby zwiększania odpowiedzi immunologicznych | |
PT2099321T (pt) | Composições de leite humano e métodos de fabrico e utilização das mesmas | |
PT2185719E (pt) | Anticorpos anti-rantes e processos para a sua utilização | |
ZA200906516B (en) | Novel human anti-R7V antibodies and uses thereof | |
EP2376089A4 (fr) | Compositions de vaccins contre le cancer et leurs méthodes d' utilisation | |
ZA201101214B (en) | Formulations of canfosfamide and their preparation | |
EP2381929A4 (fr) | Composition pharmaceutique d'une formule lyophilisée et sa méthode d'élaboration | |
ZA200909090B (en) | Lyophilized immunoglobulin formulations and methods of preparation | |
IL186277A0 (en) | Dnt-maleate and methods of preparation thereof | |
IL192552A0 (en) | Dnt-succinate and methods of preparation thereof | |
IL192553A0 (en) | Dnt-fumarate and methods of preparation thereof | |
IL190726A0 (en) | Dnt-benzenesulfonate and methods of preparation thereof | |
AU2007906531A0 (en) | Methods and Preparation and Uses of Xanthorrhoeaceae Compositions |